Comparison of efficacy and safety between intravaginal misoprostol versus intracervical dinoprostone for labor induction at term: Randomized Control Trial

Abstract

Induction of labor should be used in the most efficient way possible that will result in a favourable obstetric outcome with minimum fetal morbidity. This study was conducted at Obstetrics & Gynecology department; Ain shams University, maternity hospital in the period of time between April 2016 to December 2016. The aim of this study is to compare the efficacy and safety of a dose of 25μg intravaginal misoprostol versus 3mg intracervical dinoprostone in induction of labor at term. The total number of patients studied was 150 patients, divided into two groups; the first group (A) included 75 patients who received vaginal misoprostol 25 μg every 4hours for a maximum of 3 doses, the second group (B) included 75 patients who received dinoprostone 3mg vaginally every 6hours for a maximum of 2 doses. The current study found that misoprostol has a better chance for NVD 89.3% versus 76% in dinoprostone group, a lesser probability to CS 10.7% in misoprostol group versus 24% in dinoprostone group and a shorter induction delivery interval within 12 hours after induction (85.1% in misoprostol versus 14.1% in dinoprostone group). While both drugs were equal regarding maternal and fetal safety. Our study showed, that was safe and worthy to induce labor by the both drugs without forgetting the precautions and close observation to the mother and the fetus.